Protective Role of Silymarin in Early Doxorubicin induced Cardiac dysfunction in Children with Acute Lymphoblastic Leukemia.
Conclusion: Silymarin decreased early Doxorubicin induced left ventricular systolic function disturbances and can be recommended as adjuvant drug in patients with ALL under doxorubicin therapy.
RECOMMENDATION: Multicenter studies on large number of patients with longer duration of follow up to prove the protective effects of silymarin in early and late Doxorubicin induced cardiotoxicity.
PMID: 30073931 [PubMed - as supplied by publisher]
Source: Infectious Disorders Drug Targets - Category: Infectious Diseases Authors: Hagag AA, El Shehaby WA, El-Abasy AI, Mabrouk MM Tags: Infect Disord Drug Targets Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Antidoxidants | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Childhood Cancer | Children | Heart | Infectious Diseases | Leukemia | Milk | Milk Thistle | Pediatrics | Study